Capricor Therapeutics（CAPR）株式概要
臨床段階のバイオテクノロジー企業であるカプリコル・セラピューティクス社は、デュシェンヌ型筋ジストロフィー（DMD）およびその他のアンメット・メディカル・ニーズのある疾患を治療するための、変革的な細胞およびエクソソームに基づく治療薬の開発に米国で取り組んでいる。 詳細
CAPR Community Fair Values
Create NarrativeSee what 57 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$58
FV
89.2% 割安 内在価値ディスカウント307
users have viewed this narrative3users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
Capricor Therapeutics, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$6.29 |
| 52週高値 | US$40.37 |
| 52週安値 | US$2.96 |
| ベータ | 0.53 |
| 1ヶ月の変化 | -66.74% |
| 3ヶ月変化 | -78.21% |
| 1年変化 | -11.41% |
| 3年間の変化 | -19.05% |
| 5年間の変化 | 50.12% |
| IPOからの変化 | -85.02% |
最新ニュース
Recent updates
ナラティブ更新 • Aug 11
CAPR: Post AdCom Regulatory Outcome Will Drive 2026 Upside Potential
Capricor Therapeutics now carries a sharply reduced analyst price target of about $4.38, down from roughly $49.44, as analysts factor in the negative deramiocel AdCom vote, heightened FDA approval concerns, higher perceived risk, and lower projected profitability and P/E multiples. Analyst Commentary Recent research on Capricor Therapeutics has shifted sharply after the deramiocel advisory committee outcome, with most firms now focused on regulatory risk, legal overhangs, and reduced earnings potential.Seeking Alpha • Jul 28
Capricor Therapeutics: Downgrading To Sell As FDA Doubts Mount
Summary Capricor Therapeutics is downgraded to Sell after FDA briefing materials cast doubt on deramiocel’s efficacy in DMD cardiomyopathy. FDA highlighted that HOPE-3’s positive endpoints were only achieved after post-unblinding SAP changes, undermining statistical validity. With deramiocel’s approval in jeopardy and the rest of the pipeline in early stages, CAPR now resembles a preclinical/Phase 1 company. Despite $278.6M cash and no major debt, dilution risk looms as Capricor’s commercial prospects dim and market cap reflects higher uncertainty. Read the full article on Seeking Alphaナラティブ更新 • Jul 27
CAPR: July FDA Panel Vote Will Determine Bullish 2026 Approval Path
Capricor Therapeutics' analyst fair value estimate has been reduced from $54.67 to $49.44, as analysts factor in sharply lower price targets following critical FDA briefing documents on deramiocel, multiple downgrades to Neutral ratings, and increased concern that current data and statistical protocols may not support approval in its present form. Analyst Commentary Recent Street research on Capricor Therapeutics highlights a sharp reassessment of risk around deramiocel ahead of the upcoming FDA advisory committee meeting, with price targets and ratings moving in response to concerns over data integrity, statistical methods, and regulatory pushback.
新しいナラティブ • Jul 12
The Exosome Pioneer: Why Capricor (CAPR) is Poised for an August FDA Breakthrough
Prologue: Witnessing the Exosome Revolution in Clinical Practice As a veterinarian actively running a clinic in 2026, I have seen firsthand the disruptive power of exosome technology. Last year, I introduced an 'exosome ice-needling injection machine' at my hospital to treat some of the most stubborn conditions in small animals.
ナラティブ更新 • Jun 15
CAPR: August FDA Decision On Duchenne Therapy Will Drive Long Term Upside Potential
Capricor Therapeutics' analyst price target has been cut by $5, to $38 from $43, as analysts factor in the removal of an expected $80 million milestone payment linked to the NS Pharma dispute and a later modeled U.S. launch for Deramiocel. Analyst Commentary Bullish analysts are recalibrating their models around the NS Pharma dispute and timing of the Deramiocel U.S. launch, yet some still see meaningful potential tied to upcoming regulatory and monetization events.
ナラティブ更新 • Jun 01
CAPR: FDA Decision And HOPE-3 Data Will Drive Bullish Repricing
Analysts have trimmed their average price target on Capricor Therapeutics by about $1.60 to roughly $39.40. This reflects adjustments for the removed $80m milestone and a later modeled Deramiocel U.S. launch, while still factoring in upcoming FDA decisions and related catalysts.ナラティブ更新 • May 15
CAPR: August PDUFA Decision Will Shape Duchenne Treatment Adoption Outlook
Narrative Update: Capricor Therapeutics Analyst Price Target Shift The analyst price target for Capricor Therapeutics has been reduced by $5 to $38, as analysts factor in the removal of an expected $80 million milestone payment and a later modeled U.S. launch for Deramiocel following the company’s legal action against NS Pharma. Analyst Commentary Recent Street research around Capricor Therapeutics has shifted from purely optimistic toward a more balanced stance, as bullish analysts factor in both regulatory progress for Deramiocel and the impact of the company’s legal action against NS Pharma.ナラティブ更新 • Apr 29
CAPR: August PDUFA Cardiac Data Will Drive Bullish 2026 Approval Setup
Narrative Update: Capricor Therapeutics The updated analyst price target framework for Capricor Therapeutics moves from a prior fair value of $50.80 to $54.67. This reflects analysts' use of higher projected revenue growth, wider profit margins and a higher future P/E multiple following recent positive deramiocel data, FDA review progress and a series of target increases across the Street.ナラティブ更新 • Apr 15
CAPR: August PDUFA Decision Will Drive Bullish Duchenne Thesis
Analysts have lifted their average price targets on Capricor Therapeutics into a $41 to $63 range, supported by recent FDA progress on deramiocel for Duchenne muscular dystrophy, additional positive Phase 3 HOPE-3 data, and updated cash and review timelines that feed into modest tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions in the valuation model. Analyst Commentary Bullish analysts are largely framing recent volatility in Capricor Therapeutics as a short-term shakeout rather than a shift in the long-term story.ナラティブ更新 • Apr 01
CAPR: August PDUFA And HOPE 3 Readout Will Shape Bullish Case
Analysts have lifted their blended price target on Capricor Therapeutics to $63, supported by higher targets from several firms. These firms point to recent FDA milestones for deramiocel in Duchenne muscular dystrophy, additional Phase 3 HOPE-3 data, and updated PDUFA timing as key drivers behind their refreshed assumptions.ナラティブ更新 • Mar 18
CAPR: August PDUFA Decision And HOPE 3 Data Will Drive Bullish Outlook
Narrative Update on Capricor Therapeutics The analyst fair value estimate for Capricor Therapeutics has moved from $62.00 to $63.00, reflecting updated Street research that points to higher price targets tied to recent FDA progress for deramiocel in Duchenne muscular dystrophy and supportive Phase 3 HOPE-3 data. Analyst Commentary Recent Street research has been broadly constructive on Capricor Therapeutics, with bullish analysts highlighting regulatory milestones for deramiocel in Duchenne muscular dystrophy and updated Phase 3 HOPE-3 data as key drivers behind their views.ナラティブ更新 • Mar 03
CAPR: HOPE 3 Data And BLA Resubmission Will Drive Bullish 2026 Approval Path
Analysts now place a slightly higher implied value on Capricor Therapeutics, with their updated price target moving to $62.00. This is supported by modest tweaks to the discount rate, revenue growth assumptions, and long-term profit margin and P/E inputs.ナラティブ更新 • Feb 17
CAPR: HOPE-3 Regulatory Progress And Capital Raise Will Drive Bullish Repricing
Analysts have kept their $41.00 price target for Capricor Therapeutics unchanged, citing only minor model adjustments such as slightly different discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Capricor provided a regulatory update on its Biologics License Application for Deramiocel in Duchenne muscular dystrophy, with the FDA requesting the full Phase 3 HOPE-3 clinical study report and supporting data to address a Complete Response Letter, without asking for additional clinical studies or new patient data.ナラティブ更新 • Feb 03
CAPR: Phase 3 Duchenne Cardiac Results Will Shape Bullish 2026 Approval Path
Narrative Update The analyst price target for Capricor Therapeutics has moved from about US$44.56 to US$50.80, with analysts pointing to expectations around Phase 3 HOPE-3 data for Deramiocel in Duchenne muscular dystrophy cardiomyopathy and updated modeling assumptions as key drivers of the change. Analyst Commentary Recent Street research points to a change in how some analysts are framing risk and potential reward around Capricor Therapeutics, especially with Phase 3 HOPE-3 data for Deramiocel in Duchenne muscular dystrophy cardiomyopathy expected in Q4.ナラティブ更新 • Jan 20
CAPR: HOPE 3 Cardiac Outcome Data Will Shape Bullish Mid 2026 Approval Path
The analyst price target for Capricor Therapeutics has increased from $12 to $13, as analysts incorporate updated assumptions for Deramiocel approval in Duchenne muscular dystrophy cardiomyopathy and anticipated Phase 3 HOPE-3 cardiac outcome data. Analyst Commentary Bullish analysts are framing the price target move to US$13 as a reflection of updated expectations around Deramiocel in Duchenne muscular dystrophy cardiomyopathy rather than a broad shift in the overall story.ナラティブ更新 • Jan 06
CAPR: HOPE-3 Duchenne Cardiac Data Will Drive Bullish Repricing
Analysts have lifted their fair value estimate for Capricor Therapeutics from $12.00 to $41.00 per share, citing updated assumptions around Deramiocel approval prospects in Duchenne muscular dystrophy cardiomyopathy, following recent Street research and price target revisions. Analyst Commentary Recent Street commentary around Capricor Therapeutics has centered on expectations for Deramiocel in Duchenne muscular dystrophy cardiomyopathy, with valuation work closely tied to regulatory outcomes and clinical readouts for the Phase 3 HOPE-3 trial anticipated in Q4.ナラティブ更新 • Dec 19
CAPR: Mid 2026 Approval Path Will Drive HOPE 3 Cardiac Catalyst Narrative
Analysts have sharply increased their price target for Capricor Therapeutics, effectively more than doubling fair value from approximately $29 to about $62. They cite higher projected revenue growth, a dramatic improvement in long term profit margins, a more normalized future earnings multiple, and growing confidence that positive HOPE-3 data could support regulatory flexibility and keep a potential Deramiocel approval on track for mid 2026.ナラティブ更新 • Dec 05
CAPR: Phase 3 Duchenne Cardiac Data Will Drive 2026 Approval Hopes
Analysts have sharply raised their price target on Capricor Therapeutics, with the modeled fair value estimate climbing from about $20.60 to roughly $44.56 per share. They cite stronger expected revenue growth, significantly improved profit margins, and increasing confidence that positive HOPE-3 Phase 3 data could support Deramiocel approval for Duchenne muscular dystrophy cardiomyopathy on an accelerated mid 2026 timeline.分析記事 • Nov 05
We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...分析記事 • Sep 09
Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
To the annoyance of some shareholders, Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shares are down a considerable 30...分析記事 • Jun 24
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
To the annoyance of some shareholders, Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shares are down a considerable 25...分析記事 • May 16
Here's Why We Think Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Compensation Looks Fair
Key Insights Capricor Therapeutics to hold its Annual General Meeting on 22nd of May CEO Linda Marbán's total...分析記事 • May 09
Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
Unfortunately for some shareholders, the Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) share price has dived 26% in the...
新しいナラティブ • May 03
FDA Priority Review And NS Pharma Partnership Will Empower Deramiocel
FDA priority review of deramiocel and partnership with NS Pharma could drive significant revenue growth and market penetration.株主還元
| CAPR | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | -5.4% | 5.2% | -2.1% |
| 1Y | -11.4% | 43.5% | 18.8% |
業界別リターン: CAPR過去 1 年間で43.5 % の収益を上げたUS Biotechs業界を下回りました。
リターン対市場: CAPRは、過去 1 年間で18.8 % のリターンを上げたUS市場を下回りました。
価格変動
| CAPR volatility | |
|---|---|
| CAPR Average Weekly Movement | 29.0% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: CAPRの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: CAPRの 週次ボラティリティ は過去 1 年間で56%から29%に減少しましたが、依然としてUS株の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2005 | 231 | Linda Marbán | www.capricor.com |
Capricor Therapeutics, Inc.は臨床段階のバイオテクノロジー企業で、米国においてデュシェンヌ型筋ジストロフィー（DMD）やその他のアンメット・メディカル・ニーズのある疾患を治療するための、形質転換細胞およびエクソソームに基づく治療薬の開発に従事している。同社の主要製品候補は、同種心筋球由来の細胞であるデラミオセルで、DMDの治療薬として第3相臨床試験中である。また、SARS-CoV-2治療薬として前臨床試験中のエクソソーム・タンパク質ベース・ワクチン、StealthXエクソソーム・プラットフォーム、ワクチンや治療薬開発のための人工エクソソームからなるエクソソーム・プラットフォーム・プログラムを開発し、前臨床試験中である。さらに、さまざまな疾患の治療や予防のための標的RNA、タンパク質、低分子治療薬など、さまざまな治療応用のための第1相臨床試験中の人工エクソソームベースのワクチン候補であるStealthXの開発に取り組んでいる；ジョンズ・ホプキンス大学、ローマ大学ライセンス校、シダーズ・サイナイ・メディカル・センターとライセンス契約を結び、全分野の特許権およびノウハウの非独占的権利のもと、ライセンス製品およびライセンスサービスを開発・商業化する。同社は2005年に設立され、カリフォルニア州サンディエゴに本社を置いている。
Capricor Therapeutics, Inc. 基礎のまとめ
| CAPR 基礎統計学 | |
|---|---|
| 時価総額 | US$397.38m |
| 収益（TTM） | -US$129.42m |
| 売上高(TTM) | n/a |
0.0x
P/Sレシオ-2.8x
PER（株価収益率CAPR は割高か？
公正価値と評価分析を参照収益と収入
| CAPR 損益計算書（TTM） | |
|---|---|
| 収益 | US$0 |
| 売上原価 | US$99.73m |
| 売上総利益 | -US$99.73m |
| その他の費用 | US$29.68m |
| 収益 | -US$129.42m |
直近の収益報告
Jun 30, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -2.23 |
| グロス・マージン | 0.00% |
| 純利益率 | 0.00% |
| 有利子負債／自己資本比率 | 0% |
CAPR の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/21 00:58 |
| 終値 | 2026/08/21 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Capricor Therapeutics, Inc. 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10
| アナリスト | 機関 |
|---|---|
| Matthew Venezia | Alliance Global Partners |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Kristen Kluska | Cantor Fitzgerald & Co. |